Literature DB >> 32064527

A year of change for Journal of Molecular Cell Biology.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32064527      PMCID: PMC7050617          DOI: 10.1093/jmcb/mjaa001

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


× No keyword cloud information.
In recent years, the scientific publishing world has been significantly changed from focusing on impact factor to encouraging scientific merit and from subscriptional access to open access (Wu, 2018). Journal of Molecular Cell Biology (JMCB), which was launched in October 2009, started a new journey following the new routes in the scientific publishing world from the beginning of 2019. Here, I would like to go through what JMCB has fulfilled in the first year of change. As an academic journal, JMCB devotes itself to expressing the appreciation on the important scientific discoveries in the past and bringing the new development based on these discoveries for the future. In 2019, JMCB focused on the famous tumor suppressor gene p53, which was discovered 40 years ago. A memorial symposium with the theme ‘The Legend of p53 vs. Cancer’ was hosted by JMCB in May 2019 in Hangzhou, China (Wu, 2019; Zhang et al., 2019). In addition, two special issues on ‘p53: updates on mechanisms, biology and therapy’ (Lane and Verma, 2019a, b) and one memorial issue for celebrating the 40th anniversary of p53 discovery (Lu, 2019) were published. It is worth mentioning that a number of hard core researchers, many of whom are pioneering and world-class scientists in the fields of p53, epigenetics, and cancer, contributed to this series of events. Remarkably, Dr Arnold J. Levine, one of the p53 discoverers, delivered his perspective on p53 research after four decades, entitled ‘The many faces of p53: something for everyone’ (Levine, 2019). JMCB also recognizes that science benefits from openness. Since January 2019, JMCB has been transformed from a traditional subscription journal to a fully open access one. This transformation has significantly increased the accessibility, evidenced by the fact that the total downloads of JMCB publications per month in 2019 increased by more than 70%, compared with that in 2015–2018. In addition, JMCB allows advance posting on preprint servers, such as bioRxiv, prior to publication to help authors share their work as early as possible and receive feedback from a wider audience. We believe that open access publication of JMCB provides a more direct and efficient way for science communication, and in turn, the journal will benefit from an open scientific community. The new decade is coming! While the ecosystem of scientific publishing world is still in course of reconstruction, JMCB will do its best in this changing world and provide better service for the community.
  7 in total

1.  JMCB in the 10th year: call for changes.

Authors:  Jiarui Wu
Journal:  J Mol Cell Biol       Date:  2018-06-01       Impact factor: 6.216

2.  What's knowledge is prologue: celebrating the 40th anniversary of the p53 discovery.

Authors: 
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 6.216

3.  p53: updates on mechanisms, biology and therapy (I).

Authors:  David P Lane; Chandra S Verma
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

4.  p53: updates on mechanisms, biology and therapy (II).

Authors:  David P Lane; Chandra S Verma
Journal:  J Mol Cell Biol       Date:  2019-04-01       Impact factor: 6.216

5.  The many faces of p53: something for everyone.

Authors:  Arnold J Levine
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 6.216

6.  JMCB Symposium 2019: The Legend of p53 vs. Cancer.

Authors:  Ping Zhang; Suzanne P Christen; Gareth L Bond
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 6.216

7.  Legends of p53: untold four-decade stories.

Authors:  Hua Lu
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 8.185

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.